Joanna Tucka1, Haixiang Yu1, Kelly Gray1, Nichola Figg1, Janet Maguire1, Brian Lam1, Martin Bennett1, Trevor Littlewood2. 1. From the Divisions of Cardiovascular Medicine (J.T., H.Y., K.G., N.F., M.B., T.L.), Clinical Pharmacology (J.M.), and Metabolic Research Laboratories (B.L.), University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom; and Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom (T.L.). 2. From the Divisions of Cardiovascular Medicine (J.T., H.Y., K.G., N.F., M.B., T.L.), Clinical Pharmacology (J.M.), and Metabolic Research Laboratories (B.L.), University of Cambridge, Addenbrooke's Hospital, Cambridge, United Kingdom; and Department of Biochemistry, University of Cambridge, Cambridge, United Kingdom (T.L.). tdl2@cam.ac.uk.
Abstract
OBJECTIVE: Vascular smooth muscle cell (VSMC) apoptosis occurs at low levels in atherosclerotic plaques and in vessel remodeling; however, the consequences and mediators of these levels are not known. Akt1 protects against VSMC apoptosis largely through inactivating target proteins such as forkhead class O transcription factor 3a (FoxO3a), but Akt1 signaling is reduced and FoxO3a activity is increased in human atherosclerosis. We therefore sought to determine whether inhibition of VSMC apoptosis via Akt1 activation regulates vessel remodeling and atherogenesis and to identify FoxO3a target proteins that mediate VSMC apoptosis. APPROACH AND RESULTS: We generated mice that express an Akt1 protein that can be activated specifically in arterial VSMCs. Akt1 activation did not affect normal arteries, but inhibited VSMC apoptosis and negative remodeling after carotid ligation, indicating that VSMC apoptosis is a major determinant of vessel caliber after changes in flow. Akt1 activation inhibited VSMC apoptosis during atherogenesis and increased relative fibrous cap area in plaques. Microarray studies identified multiple FoxO3a-regulated genes involved in VSMC apoptosis, including apoptotic protease activating factor 1 as a novel target. Apoptotic protease activating factor 1 mediated the proapoptotic activity of FoxO3a, was increased in human atherosclerosis, but reduced by Akt1 activity in vivo. CONCLUSIONS: Akt1 is a major regulator of VSMC survival in vivo during vessel remodeling and atherogenesis, mediated in large part through inhibition of FoxO3a and its downstream genes, including apoptotic protease activating factor 1. Our data suggest that even the low-level VSMC apoptosis seen during changes in flow determines vessel wall structure and promotes fibrous cap thinning during atherogenesis.
OBJECTIVE: Vascular smooth muscle cell (VSMC) apoptosis occurs at low levels in atherosclerotic plaques and in vessel remodeling; however, the consequences and mediators of these levels are not known. Akt1 protects against VSMC apoptosis largely through inactivating target proteins such as forkhead class O transcription factor 3a (FoxO3a), but Akt1 signaling is reduced and FoxO3a activity is increased in human atherosclerosis. We therefore sought to determine whether inhibition of VSMC apoptosis via Akt1 activation regulates vessel remodeling and atherogenesis and to identify FoxO3a target proteins that mediate VSMC apoptosis. APPROACH AND RESULTS: We generated mice that express an Akt1 protein that can be activated specifically in arterial VSMCs. Akt1 activation did not affect normal arteries, but inhibited VSMC apoptosis and negative remodeling after carotid ligation, indicating that VSMC apoptosis is a major determinant of vessel caliber after changes in flow. Akt1 activation inhibited VSMC apoptosis during atherogenesis and increased relative fibrous cap area in plaques. Microarray studies identified multiple FoxO3a-regulated genes involved in VSMC apoptosis, including apoptotic protease activating factor 1 as a novel target. Apoptotic protease activating factor 1 mediated the proapoptotic activity of FoxO3a, was increased in human atherosclerosis, but reduced by Akt1 activity in vivo. CONCLUSIONS: Akt1 is a major regulator of VSMC survival in vivo during vessel remodeling and atherogenesis, mediated in large part through inhibition of FoxO3a and its downstream genes, including apoptotic protease activating factor 1. Our data suggest that even the low-level VSMC apoptosis seen during changes in flow determines vessel wall structure and promotes fibrous cap thinning during atherogenesis.
Authors: Noemi Rotllan; Amarylis C Wanschel; Ana Fernández-Hernando; Alessandro G Salerno; Stefan Offermanns; William C Sessa; Carlos Fernández-Hernando Journal: Circ Res Date: 2015-04-13 Impact factor: 17.367
Authors: Yu Jin; Yi Xie; Allison C Ostriker; Xinbo Zhang; Renjing Liu; Monica Y Lee; Kristen L Leslie; Waiho Tang; Jing Du; Seung Hee Lee; Yingdi Wang; William C Sessa; John Hwa; Jun Yu; Kathleen A Martin Journal: Arterioscler Thromb Vasc Biol Date: 2017-10-12 Impact factor: 8.311